Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature

Critical Reviews in Oncology/hematology
María Teresa MartínezAna Lluch

Abstract

Trastuzumab emtansine (T-DM1), a new agent developed for the treatment of HER2-positive breast cancer, is an antibody-drug conjugate with a complex compound obtained by the conjugation of trastuzumab, a stable thioether linker, and the potent cytotoxic drug maytansine-derivate(DM1), which inhibits cell division and induces cell death. PubMed database, ESMO, ASCO, San Antonio Breast Cancer Symposium Meeting abstracts and clinicaltrials.gov were searched using the terms "Anti-HER2 treatment breast cancer and trastuzumab emtansine (T-DM1) "; papers considered relevant for the aim of this review were selected. The phase I trials have determined the safe dosing range of T-DM1, established at 3.6mg/kg every 3 weeks. The phase III randomized EMILIA and TR3RESA trials have shown that T-DM1 provides objective tumor responses and significantly improves progression free survival and overall survival in HER2-positive metastatic breast cancer patients previously treated with anti-HER2-based regimens. The ongoing phase III trials KAITLIN and KATHERINE will give us further information about the place T-DM1 should occupy in the treatment of patients with early stage HER2-positive breast cancer. In this review we analyze the most relevant clini...Continue Reading

References

Jan 7, 2000·Journal of Cellular Physiology·S MénardS M Pupa
Feb 28, 2003·Nature Structural Biology·Mark X Sliwkowski
Jan 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jenny C Chang
Apr 19, 2007·Journal of the National Cancer Institute·Maurizio ScaltritiJosé Baselga
Aug 19, 2008·Oncology·Hamdy Azim, Hatem A Azim
Nov 18, 2008·Cancer Research·Gail D Lewis PhillipsMark X Sliwkowski
Jul 10, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F CardosoUNKNOWN ESMO Guidelines Working Group
Mar 4, 2010·Cancer Research·Yelena V KovtunRavi V J Chari
Apr 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian E KropHoward A Burris
Aug 7, 2010·The Lancet Oncology·Charles M PerouPhilip S Bernard
Sep 4, 2010·Breast Cancer Research : BCR·Aleix PratCharles M Perou
Dec 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard A BurrisJoyce A O'Shaughnessy
Oct 2, 2012·The New England Journal of Medicine·Sunil VermaUNKNOWN EMILIA Study Group
Feb 14, 2013·Current Medical Research and Opinion·Baris BoyrazKadri Altundag
Mar 9, 2013·Future Oncology·Parvin F Peddi, Sara A Hurvitz
Oct 19, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ian Krop, Eric P Winer
Dec 20, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R BartschUNKNOWN Biotherapy Development Association (BDA)
Dec 24, 2013·The Breast : Official Journal of the European Society of Mastology·Maria Cristina Figueroa-MagalhãesAntonio C Wolff
Apr 16, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kathy D MillerHoward A Burris
May 7, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sharon H GiordanoUNKNOWN American Society of Clinical Oncology
Jun 1, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Laleh Amiri-KordestaniPatricia Cortazar
Jun 27, 2014·Journal of Medicinal Chemistry·John M Lambert, Ravi V J Chari
Sep 19, 2014·World Journal of Gastrointestinal Oncology·Ambedkar Raj Kulandai VeluIlavarasi Sinduja

❮ Previous
Next ❯

Citations

Nov 25, 2016·Expert Review of Anticancer Therapy·Matteo LambertiniEvandro de Azambuja
Dec 17, 2016·International Journal of Molecular Sciences·Quanxia LvGe Zhang
May 21, 2017·Biochemical and Biophysical Research Communications·Osamu MorimuraAtsushi Kumanogoh
Dec 7, 2017·ESMO Open·Claire M Connell, Gary J Doherty
Feb 8, 2019·Expert Opinion on Pharmacotherapy·Palma FedeleSaverio Cinieri
Mar 12, 2020·Immunotherapy·Amrita Basu, Krithika Kodumudi
May 5, 2016·Physiological Reviews·Andreas WickiGongda Xue
Nov 5, 2017·Journal of Experimental & Clinical Cancer Research : CR·Carolina D'AlesioPatrizio Castagnola
May 24, 2020·Communications Biology·Rozanne ArulanandamJean-Simon Diallo
Apr 5, 2016·Clinical Medicine Insights. Oncology·María Luque-CabalIsabel Palacio-Vázquez
Jun 26, 2020·Pharmacology Research & Perspectives·Juliette SauveurCharles Dumontet
May 18, 2018·Animal Science Journal = Nihon Chikusan Gakkaihō·Kazunori OyamaTomokazu Fukuda
Nov 16, 2016·ESMO Open·Noam F PondéEvandro de Azambuja
Aug 14, 2020·The Journal of Steroid Biochemistry and Molecular Biology·María Julia FerronatoAlejandro Carlos Curino
May 1, 2021·International Journal of Molecular Sciences·Vrinda GoteDhananjay Pal
Jul 1, 2021·Future Oncology·Marc PeetersHarah Jang
Sep 14, 2021·Journal of Biomolecular Structure & Dynamics·Toheeb Adewale BalogunDamilola Alex Omoboyowa
Nov 7, 2021·Nature Communications·Olav EngebraatenAnette Weyergang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.